This article is more than 5 years old. Information may no longer be current.

Study: Low-dose SoluMatrix diclofenac improves patient-reported OA pain

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patients with osteoarthritis reported improved pain scores and physical function after treatment with SoluMatrix diclofenac capsules through a 52-week dosing period, according to research findings.

Researchers studied 601 patients older than 40 years of age with hip and/or knee osteoarthritis (OA) and chronic use of NSAIDs or acetaminophen for pain. Health-related quality of life was evaluated using SF-36 scores at baseline, 12, 24, 32, 40, 48 and 52 weeks, or at early termination from the study.

Vibeke Strand

During the study period, 299 patients (49.8%) completed treatment with SoluMatrix diclofenac 35-mg capsules twice per day. Three hundred two patients (50.2%) increased the dosage to 35 mg three times per day at least once during treatment, in most cases (67.7%) to achieve greater analgesia. Of those who increased their dosage, 20.6% returned to twice-per-day doses after achieving satisfactory analgesia.

Physical Component Scores on the SF-36 improved, on average, by 2.5 points or greater through 52 weeks. Bodily Pain Domain scores improved on average by 5 points or more, and physical functioning and role physical scores improved by 4.3 and 3.6 points, respectively, according to the researchers. Twelve patients withdrew due to lack of efficacy. – by Shirley Pulawski

Reference:

Strand V, et al. Paper #249. Presented at: American College of Rheumatology Annual Meeting. Nov. 14-19, 2014; Boston.

Disclosure: Strand is a consultant for AbbVie, Afferent, Amgen, Biogen Idec, Bioventus, BMS, Carbylan, Celgene, Celltrion, CORRONA, Crescendo, Genentech/Roche, GSK, Hospira, Iroko, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, SKK, Takeda, UCB and Vertex. Please see the full study for a list of all other authors’ relevant financial disclosures.